Synthorx, a preclinical biotech developing immunotherapies for solid tumors and autoimmune disorders, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
The La Jolla, CA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol THOR. Jefferies, Leerink Partners and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
